ArticleBioconjugate chemistry2011
Comparison study of [18F]FAl-NOTA-PRGD2, [18F]FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice.
Article in Bioconjugate chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed.
- Application of (68)Ga-PRGD2 PET/CT for αvβ3-integrin imaging of myocardial infarction and stroke.Theranostics · 2014Trial
- First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Trial
- Unique fluoroalkyl substituents: is there life after CFChemical science · 2026Review
- Fibroblast activation protein targeting radiopharmaceuticals: From drug design to clinical translation.Acta pharmaceutica Sinica. B · 2025Review
- Development of [European journal of nuclear medicine and molecular imaging · 2024Article
- Sortase-Mediated Site-Specific Conjugation to Prepare Fluorine-18-Labeled Nanobodies.Bioconjugate chemistry · 2024Article
- EGFR- and Integrin αInternational journal of molecular sciences · 2024Review
- Ultrasensitive detection of uveal melanoma using [EJNMMI research · 2024Article
- Clinical translation of a novel FAPI dimer [European journal of nuclear medicine and molecular imaging · 2024Article
- Deoxyfluorination of phenols for chemoselectiveNature protocols · 2023Review
- Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.RSC medicinal chemistry · 2023Review
- Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.International journal of molecular sciences · 2023Review
- [Frontiers in oncology · 2023Article
- Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics.Theranostics · 2022Article
- Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose.Frontiers in medicine · 2022Review
- Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors.Frontiers in oncology · 2022Review
- The aluminium-[EJNMMI radiopharmacy and chemistry · 2021Review
- PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin αMolecules (Basel, Switzerland) · 2021Review
- The Feasibility of Targeted Magnetic Iron Oxide Nanoagent for Noninvasive IgA Nephropathy Diagnosis.Frontiers in bioengineering and biotechnology · 2021Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
[(18)F]FPPRGD2, an F-18 labeled dimeric cyclic RGDyK peptide, has favorable properties for PET imaging of angiogenesis by targeting the α(v)β(3) integrin receptor. This radiotracer has been approved by the FDA for use in clinical trials. However, the time-consuming multiple-step synthetic procedure required for its preparation may hinder the widespread usage of this tracer. The recent development of a method using an F-18 fluoride-aluminum complex to radiolabel peptides provides a strategy for simplifying the labeling procedure. On the other hand, the easy-to-prepare [(68)Ga]-labeled NOTA-RGD derivatives have also been reported to have promising properties for imaging α(v)β(3) integrin receptors. The purpose of this study was to prepare [(18)F]FPPRGD2 [corrected] , [(18)F]FAl-NOTA-PRGD2, and [(68)Ga]Ga-NOTA-PRGD2 and to compare their pharmacokinetics and tumor imaging properties using small animal PET. All three compounds showed rapid and high tracer uptake in U87MG tumors with high target-to-background ratios. The uptake in the liver, kidneys, and muscle were similar for all three tracers, and they all showed predominant renal clearance. In conclusion, [(18)F]FAl-NOTA-PRGD2 and [(68)Ga]Ga-NOTA-PRGD2 have imaging properties and pharmacokinetics comparable to those of [(18)F]FPPRGD2. Considering their ease of preparation and good imaging qualities, [(18)F]FAl-NOTA-PRGD2 and [(68)Ga]NOTA-PRGD2 are promising alternatives to [(18)F]FPPRGD2 for PET imaging of tumor α(v)β(3) integrin expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.